Cargando…

Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma

Glioblastoma multiforme (GBM) is the most frequent and malignant primary central nervous system tumor in adults. The gold-standard management of GBM includes post-operative radiotherapy (RT) with concurrent and secondary temozolomide (TMZ) treatment. The present meta-analysis study examined the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aravantinou-Fatorou, Aikaterini, Georgakopoulou, Vasiliki Epameinondas, Mathioudakis, Nikolaos, Papalexis, Petros, Tarantinos, Kyriakos, Trakas, Ilias, Trakas, Nikolaos, Spandidos, Demetrios A., Fotakopoulos, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442729/
https://www.ncbi.nlm.nih.gov/pubmed/37614373
http://dx.doi.org/10.3892/mco.2023.2669
_version_ 1785093666418720768
author Aravantinou-Fatorou, Aikaterini
Georgakopoulou, Vasiliki Epameinondas
Mathioudakis, Nikolaos
Papalexis, Petros
Tarantinos, Kyriakos
Trakas, Ilias
Trakas, Nikolaos
Spandidos, Demetrios A.
Fotakopoulos, George
author_facet Aravantinou-Fatorou, Aikaterini
Georgakopoulou, Vasiliki Epameinondas
Mathioudakis, Nikolaos
Papalexis, Petros
Tarantinos, Kyriakos
Trakas, Ilias
Trakas, Nikolaos
Spandidos, Demetrios A.
Fotakopoulos, George
author_sort Aravantinou-Fatorou, Aikaterini
collection PubMed
description Glioblastoma multiforme (GBM) is the most frequent and malignant primary central nervous system tumor in adults. The gold-standard management of GBM includes post-operative radiotherapy (RT) with concurrent and secondary temozolomide (TMZ) treatment. The present meta-analysis study examined the efficacy of the early administration of bevacizumab prior to standard RT plus TMZ in managing patients with GBM and unfavorable prognostic factors. Between 1983 and 2020, the present study looked for comparative articles involving standard RT plus TMZ and RT/TMZ combined with bevacizumab treatment in patients with GBM. The primary outcomes involved in this study include progression-free survival and overall survival. The present study suggested that bevacizumab administration plus standard RT/TMZ (BEV group) treatment was associated with increased survival of patients with GBM compared with those treated with standard RT/TMZ (CG/Control group) treatment only.
format Online
Article
Text
id pubmed-10442729
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-104427292023-08-23 Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma Aravantinou-Fatorou, Aikaterini Georgakopoulou, Vasiliki Epameinondas Mathioudakis, Nikolaos Papalexis, Petros Tarantinos, Kyriakos Trakas, Ilias Trakas, Nikolaos Spandidos, Demetrios A. Fotakopoulos, George Mol Clin Oncol Articles Glioblastoma multiforme (GBM) is the most frequent and malignant primary central nervous system tumor in adults. The gold-standard management of GBM includes post-operative radiotherapy (RT) with concurrent and secondary temozolomide (TMZ) treatment. The present meta-analysis study examined the efficacy of the early administration of bevacizumab prior to standard RT plus TMZ in managing patients with GBM and unfavorable prognostic factors. Between 1983 and 2020, the present study looked for comparative articles involving standard RT plus TMZ and RT/TMZ combined with bevacizumab treatment in patients with GBM. The primary outcomes involved in this study include progression-free survival and overall survival. The present study suggested that bevacizumab administration plus standard RT/TMZ (BEV group) treatment was associated with increased survival of patients with GBM compared with those treated with standard RT/TMZ (CG/Control group) treatment only. D.A. Spandidos 2023-07-26 /pmc/articles/PMC10442729/ /pubmed/37614373 http://dx.doi.org/10.3892/mco.2023.2669 Text en Copyright: © Aravantinou-Fatorou et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Aravantinou-Fatorou, Aikaterini
Georgakopoulou, Vasiliki Epameinondas
Mathioudakis, Nikolaos
Papalexis, Petros
Tarantinos, Kyriakos
Trakas, Ilias
Trakas, Nikolaos
Spandidos, Demetrios A.
Fotakopoulos, George
Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
title Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
title_full Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
title_fullStr Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
title_full_unstemmed Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
title_short Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
title_sort comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442729/
https://www.ncbi.nlm.nih.gov/pubmed/37614373
http://dx.doi.org/10.3892/mco.2023.2669
work_keys_str_mv AT aravantinoufatorouaikaterini comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT georgakopoulouvasilikiepameinondas comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT mathioudakisnikolaos comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT papalexispetros comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT tarantinoskyriakos comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT trakasilias comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT trakasnikolaos comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT spandidosdemetriosa comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma
AT fotakopoulosgeorge comparisonoftheoutcomesfollowingbevacizumabandortemozolamideradiosurgerytreatmentinpatientswithglioblastoma